AMYLINDERIVATE

European patent · EP2718316 · In force

Register entry

Publication number
EP2718316
Application number
EP12729418
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Jun 8, 2012
Published
Apr 16, 2014
Granted
Dec 4, 2019
Protection ends at the latest
Jun 7, 2032
Next annual fee due
Jun 30, 2027
IPC classes
C07K 14/575 (2006.01)
A61K 38/22 (2006.01)
A61K 47/54 (2017.01)
A61K 38/00 (2006.01)
Priority
EP 11169405 10.06.2011
US 201161496113 P 13.06.2011
PCT application
PCT/EP2012/060900 08.06.2012
PCT publication
WO2012/168432 13.12.2012
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Jul 1, 2026

    Next annual fee due on

    Next annual fee due on
    30.06.2026 → 30.06.2027

    Published in Swissreg on 01.07.2026

  2. Jul 1, 2025

    Next annual fee due on

    Next annual fee due on
    30.06.2025 → 30.06.2026

    Published in Swissreg on 01.07.2025

  3. Jul 1, 2024

    Change

    Published in Swissreg on 01.07.2024

  4. Jul 1, 2023

    Change

    Published in Swissreg on 01.07.2023

  5. Jul 1, 2022

    Change

    Published in Swissreg on 01.07.2022

  6. Dec 4, 2019

    Granted

    Published in Swissreg on 04.12.2019

Parties

Holder

Novo Nordisk A/S

Novo Allé, 2880 Bagsværd, DK

Inventor

KRUSE, Thomas

DK-2880 Bagsværd, DK

THØGERSEN, Henning

DK-2880 Bagsværd, DK

SCHÄFFER, Lauge

DK-2880 Bagsværd, DK

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.